Among these, DNMT inhibitors azacytidine, guadecitabine (SGI-110), and decitabine have already entered clinical trials.66,67 In 2018, a phase III clinical trial of azacitidine has been completed to evaluate its safety profile and to determine whether azacitidine can cure patients with acute myeloid leukemia (AML), chronic myelomonocytic leukemia (CMML) or myelodysplastic syndromes (MDS) following allogeneic (donor) stem cell transplantation (ClinicalTrials.gov Identifier: NCT00887068). This evidence concerns the gene DNMT1 and acute myeloid leukemia.